Syngene announces commissioning of first phase of R&D center in Hyderabad

Syngene currently operates through multiple facilities in Bengaluru spread across an area of 1.5 million square feet

Syngene
Syngene | Photo: Website of Syngene
BS Reporter Hyderabad
1 min read Last Updated : Feb 17 2020 | 8:52 PM IST
Global contract research organisation Syngene International Limited on Monday announced the commissioning of the first phase of its new R&D center in Hyderabad. The center, located in Genome Valley, is spread across 52,000 square feet with an initial strength of around 150 scientists.

This is the company's first operational research center outside Bengaluru. When fully commissioned by the end of this year at an investment of Rs 167 crore, it will cover a total of 94,000 square feet and house around 270 scientists, the company said. State IT and industry minister K T Rama Rao inaugurated the facility.

Syngene managing director Kiran Mazumdar Shaw said, "We are delighted to set up our new R&D center in Genome Valley, Telangana, recognised a a leading global biotech hub. I congratulate the government of Telangana on their vision and pioneering efforts to create an environment that fosters the growth and development of the biotechnology industry.

Syngene currently operates through multiple facilities in Bengaluru spread across an area of 1.5 million square feet comprising research and manufacturing facilities.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :SyngeneSyngene International

Next Story